These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25404506)

  • 1. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 6. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review of Ovarian Serous Carcinoma.
    Hatano Y; Hatano K; Tamada M; Morishige KI; Tomita H; Yanai H; Hara A
    Adv Anat Pathol; 2019 Sep; 26(5):329-339. PubMed ID: 31368906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Montemorano L; Shultz ZB; Farooque A; Hyun M; Chappell RJ; Hartenbach EM; Lang JD
    Gynecol Oncol; 2024 Jul; 186():26-34. PubMed ID: 38555766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whence High-Grade Serous Ovarian Cancer.
    Kohn EC; Ivy SP
    Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
    Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
    Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.